Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
164 hedge funds and large institutions have $447M invested in Catalyst Pharmaceutical in 2021 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 51 increasing their positions, 60 reducing their positions, and 13 closing their positions.
4,250% more call options, than puts
Call options by funds: $261K | Put options by funds: $6K
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
29% more capital invested
Capital invested by funds: $345M → $447M (+$102M)
14% more funds holding
Funds holding: 144 → 164 (+20)
0.74% more ownership
Funds ownership: 63.28% → 64.02% (+0.74%)
15% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$4.25M |
| 2 |
Two Sigma Advisers
New York
|
+$3.19M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.14M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.88M |
| 5 |
Renaissance Technologies
New York
|
+$2.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$7.94M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.7M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.07M |
| 4 |
AC
Armistice Capital
New York
|
-$2.81M |
| 5 |
RA
Royce & Associates
New York
|
-$2.78M |
CPRX Hedge Fund Activity: Q4 2021 in Review
164 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2021, worth a combined $447M — up 29% from $345M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CPRX positions and 13 closed out — a net gain of 20 holders — while 51 added to existing stakes and 60 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $4.25M. The largest seller was LSV Asset Management, cutting an estimated $7.94M.
- 164 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2021, up from 144 in Q3 2021.
- Funds reported $447M of Catalyst Pharmaceutical stock for Q4 2021, up 29% quarter-over-quarter.
- 33 funds opened new Catalyst Pharmaceutical positions in Q4 2021 and 13 closed out, a net change of +20 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2021 was Two Sigma Investments, an estimated $4.25M added.
- The largest Catalyst Pharmaceutical seller in Q4 2021 was LSV Asset Management, an estimated $7.94M sold.
Based on aggregated 13F filings for Q4 2021.